Contribution of integrase inhibitor use, body mass index, physical activity and caloric intake to weight gain in people living with HIV
Giovanni Guaraldi(University of Modena and Reggio Emilia), Kristine M. Erlandson(University of Colorado Anschutz Medical Campus), Marianna Menozzi(University of Modena and Reggio Emilia), Stefano Guaraldi(University of Modena and Reggio Emilia), Elena Bacchi(University of Modena and Reggio Emilia), Michela Belli(Azienda Ospedaliero-Universitaria di Modena), Jordan E. Lake(The University of Texas Health Science Center at Houston), Giacomo Ciusa(University of Modena and Reggio Emilia), Iacopo Franconi(University of Pisa), Federica Carli, Cristina Mussini(University of Modena and Reggio Emilia), Jovana Milić(University of Modena and Reggio Emilia), Maria Mancini(Champions Oncology (United States)), Alessandro Raimondi, Valentina Masi(University of Modena and Reggio Emilia), Emanuele Aprile(Azienda Ospedaliero-Universitaria di Modena)
Cited by 4
Related Papers
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|The Lancet Rheumatology|2020|995
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by<i>Klebsiella pneumoniae</i>Carbapenemase–producing<i>K. pneumoniae</i>
|Clinical Infectious Diseases|2018|351
Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada
|Journal of the International AIDS Society|2020|242
HHV-6A in Syncytial Giant-Cell Hepatitis
|New England Journal of Medicine|2008|102